Medline (Nasdaq:MDLN) posted second quarter results today, beating the consensus forecast and raising its sales outlook for the rest of the year while cutting its EBITDA outlook, citing inflationary pressure from the Middle East conflict and higher operational investments. The quarter’s results were also weighed down by a fire at its Tracy, California distribution center and tariff-related costs.
Shares of MDLN were down 5.53% to $36.51 apiece today in early trading.
The Illinois-based healthcare manufacturer — one of the largest medical device companies in the world — reported net income of $139 million, or 7¢ per share, on net sales of $7.7 billion for the three months ended June 27, 2026, for a bottom-line decrease of 58.3% and sales growth of 11.6% compared with Q2 2025.
Adjusted to exclude one-time items, earnings per share were 50¢, 18¢ ahead of MarketBeat, where analysts were expecting EPS of 32¢.
“Our second quarter results reflect strong execution of our growth strategy, and the operational resilience of our team,” CEO Jim Boyle said in a release. “We delivered robust top-line growth in the quarter, secured over 65% of our annual goal in total new customer signings4 during the first half of 2026, and moved swiftly to minimize disruption from the fire at our Tracy, California distribution center, demonstrating an unwavering commitment to our customers.”
Medline updated its full year 2026 outlook for organic sales to 9% to 10%, compared to its previous outlook of 8.5% to 9.5% and its Adjusted EBITDA outlook to $3.3 billion to $3.4 billion, compared to its previous outlook of $3.5 billion to $3.6 billion.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.